Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, etc.); or binds serum protein, plasma protein (e.g., tPA, etc.), or fibrin

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424130100 - IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL

424141100 - Monoclonal antibody or fragment thereof (i.e., produced by any cloning technology)

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20090214562Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection - The present invention encompasses a therapeutic combination composition of a β-glucan EGF receptor antagonist. This therapeutic combination composition is useful for the treatment of diseases including proliferative disorders and immune dysfunction.08-27-2009
20090214563TREATMENT FOR ANTIPHOSPHOLIPID-SYNDROME-RELATED PREGNANCY COMPLICATIONS - The present application provides compositions and methods for treating antiphospholipid-syndrome-related pregnancy complications with tissue factor antagonists.08-27-2009
20090311267Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks - The invention relates generally to an anti-thrombotic treatment of occlusive syndromes in the cerebral vascular system causing cerebral infarct due to stroke or ischemic stroke, which is a major cause of death and permanent disability in industrialized countries. More particularly, the invention relates to a system and method of preventing and treating such occlusive syndromes in the cerebral vascular by inhibiting initial adhesion/attachment of platelets to the endothelium by preventing or inhibiting binding of von Willebrand factor to platelet glycoprotein Ib by administration of a subject in such need anti-glycoprotein Ib monovalent antibodies and/or anti-vWF monovalent antibodies, rather than by blocking the common pathway of platelet aggregation by blockade of platelet aggregation with anti-glycoprotein IIb/IIIa.12-17-2009
20100080810METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES - The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.04-01-2010
20090191215Treatment with anti-VEGF Antibodies - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.07-30-2009
20090191214ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES - Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells T07-30-2009
20120177655ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES - Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells T07-12-2012
20130084299METHODS - The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.04-04-2013
20130078258Cachexia Treatment - Administration of an antibody that specifically binds IL-1α is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.03-28-2013
20100111964PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS - This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders.05-06-2010
20090155285TGF-BETA BINDING ANTIBODIES - The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.06-18-2009
20090155284HGF-SF MONOCLONAL ANTIBODY COMBINATIONS - The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.06-18-2009
20100068212Targeting pathogenic monocytes - The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.03-18-2010
20130039921Treatment of Inflammatory Skin Disease and Psychiatric Conditions - The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. Anxiety and other psychiatric conditions are also improved with this treatment.02-14-2013
20100143370SET OF MEANS FOR TREATING A MALIGNANT PATHOLOGY, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE - Kit of parts for treating a malignant pathology, an auto-immune disease or an infectious disease, comprising an effector cell which expresses the FcγRIII receptor (CD16) on its surface, and a monoclonal antibody, the affinity of the Fc region of said monoclonal antibody for CD16 being greater than the affinity of the Fc region of the polyclonal immunoglobulins for CD16.06-10-2010
20130089561EPITOPE REGIONS OF A THYROTROPHIN (TSH) RECEPTOR, USES THEREOF AND ANTIBODIES THERETO - The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto.04-11-2013
20090246206BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein the binding of each domain to its respective cell surface marker increases or decreases, as desired, the biological activity of the respective cell surface markers. The invention further provides bispecific binding agents for use in the methods, as well as uses for the agents.10-01-2009
20090304707MONOCLONAL ANTIBODIES TO BASIC FIBROBLAST GROWTH FACTOR - The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.12-10-2009
20110008359MONOCLONAL ANTIBODIES AGAINST ANGPTL4 - Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.01-13-2011
20130164301TREATMENT OF DISEASES LINKED TO PATHOLOGICAL KININ FORMATION - The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.06-27-2013
20090285826COMBINATION DRUGS COMPRISING VEGF INHIBITOR AND SERINE PROTEASES/THROMBOLYTIC COMPOUNDS FOR TREATING NEOVASCULAR DISORDERS - Pharmaceutical compositions for inhibiting, preventing or treating unwanted angiogenesis/neovascularization, including that of ocular tissues, contain agents that inhibit VEGF in combination with a second therapy, e.g., that elicited by serine proteases/thrombolytic compounds.11-19-2009
20110014205METHODS AND COMPOSITIONS FOR TREATING CHRONIC PELVIC PAIN SYNDROME - The present invention provides methods and compositions for treating chronic pelvic pain syndrome. In particular, the present invention provides methods and compositions for treating chronic pelvic pain syndrome with an agent that targets MCP-1, MIP-1α, or the CCR-2 receptor.01-20-2011
20110014204Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2 - The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.01-20-2011
20090269354QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT - This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.10-29-2009
20090317402ANTIBODIES TO IL-6 AND THEIR USES - Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.12-24-2009
20120231012Diagnosis, treatment, and prevention of vascular disorders using interleukin-1 autoantibodies - Method of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1α autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1α autantibodies.09-13-2012
20090022731Arthritis-associated B cell gene expression - The invention features methods and compositions benefiting from differential gene expression observed in arthritis-associated B cells.01-22-2009
20090148459Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents - The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin α06-11-2009
20090291087MODULATING ANGIOGENESIS - Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye.11-26-2009
20090220521Anti MIF Antibodies - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.09-03-2009
20090098139Combination therapy for the treatment of neovascular disorders - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a combination of VEGF antagonists to the patient. The invention also features a pharmaceutical composition containing a first VEGF antagonist and a second VEGF antagonist for the treatment or prevention of a neovascular disorder.04-16-2009
20090263402Growth Differentiation Factor-11 - A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-11 (GDF-11) chromosomally integrated into the germ cells of the animal is provided. Also provided are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-11. The animals so treated are characterized by increased muscle tissue and bone tissue.10-22-2009
20090263401USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE - Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described.10-22-2009
20090280130METHOD FOR THE TREATMENT OF ANTHRAX TOXICITY - is a spore-forming Gram positive bacterium that is the causative agent of anthrax infection. Vascular leakage and pleural effusions are hallmarks of the fulminant phase of human anthrax disease following infection. The present invention provides a method of halting, treating, and preventing the rapid toxic effects of human anthrax disease by blocking the VEGF pathway with chemical inhibitors of the VEGFR signaling pathway. The invention is also applicable as an anti-anthrax therapeutic in bio-warfare defense.11-12-2009
20090202558TNFalpha-NEUTRALIZING ANTIBODIES - The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.08-13-2009
20100129375METHODS FOR INHIBITING OCULAR ANGIOGENESIS - The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.05-27-2010
20080274119Use of Opioid Antagonists to Attenuate Endothelial Cell Proliferation and Migration - The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.11-06-2008
20080286282Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor - The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.11-20-2008
20080206255ANTIBODY CANCER IMMUNOTHERAPY - A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.08-28-2008
20080248049TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.10-09-2008
20080279860Treatment With Anti-VEGF Antibodies - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.11-13-2008
20100136019MODULATING REGULATORY T CELL ACTIVITY VIA INTERLEUKIN 35 - Methods for regulating T cell function in a subject, particularly regulatory T cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an Interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor. The invention further provides methods for enhancing the immunogenicity of a vaccine or overcoming a suppressed immune response to a vaccine in a subject, including administering to the subject a therapeutically effective amount of an IL35-specific binding agent and administering to the subject a vaccine. In one embodiment the vaccine is a cancer vaccine.06-03-2010
20100136020USES OF IL-174 ANTAGONISTS FOR INHIBITING A TH2 IMMUNE RESPONSE - Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described.06-03-2010
20100291098Diabetic nephropathy therapies - The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.11-18-2010
20090081232METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES - The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.03-26-2009
20090004200Combination treatment of pancreatic cancer - A combination for use in the treatment of pancreatic cancer comprising: 01-01-2009
20090004199ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.01-01-2009
20090117127Novel Compounds and Methods for Their Production - The present invention relates to 11-O-desmethylmacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies.05-07-2009
20100260767Composition and Method for Treating Inflammatory Disorders - Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.10-14-2010
20100239590JOINT DESTRUCTION BIOMARKERS FOR ANTI-IL-17A THERAPY OF INFLAMMATORY JOINT DISEASE - Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases.09-23-2010
20080206257Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor - The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.08-28-2008
20120141495METHOD FOR SUPPRESSING TUMOR GROWTH BY BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR, AND METHOD FOR DIAGNOSING MALIGNANT NEOPLASMS - The invention pertains to the field of medicine, particularly to methods for suppressing the growth of tumors, which comprise blocking the pathological pathway of human fibroblast growth factor/receptor 1 (domains II and IIIc), and for diagnosing malignant neoplasms leading to an excessive proliferation of tumor cells and to the formation of new vessels accompanied by the growth of primary tumors and metastases. This pathway also represents an independent mechanism of tumor resistance to preparations acting on other pathological pathways. Blocking the aforementioned pathway using various substances that neutralize the receptor by bonding only with domains II and IIIc thereof results in the interruption or slow-down of tumor growth. This receptor can also be used as a target for delivery of diagnostic agents being largely present in tumor cells. The invention enables developing new agents for diagnosing and treating diseases related to excessive proliferation and neovascularization.06-07-2012
20120195906METHOD FOR DIAGNOSING AND TREATING EMPHYSEMA - The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3.08-02-2012
20130129745ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.05-23-2013
20090214565Anti-Interferon Alpha Monoclonal Antibodies and Methods For Use - The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.08-27-2009
20090214564ANTI-EPHRINB2 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies.08-27-2009
20110027290ANTI-IL-17 ANTIBODIES - Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.02-03-2011
20110110953Compound and method for treatment of chronic transplant rejection - Methods of treating chronic allograft rejection are provided in the present invention. The method uses anti-CTGF agents, particularly anti-CTGF antibodies, to reduce or reverse the occurrence of fibrosis in the allograft providing prolonged survival of the transplanted organ or tissue.05-12-2011
20110117102Therapeutic uses of inhibitors of RTP801 - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.05-19-2011
20110212099METHODS OF MODULATING IL-22 AND IL-17 - The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-2309-01-2011
20110064744PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods for preventing or treating pain are provided, comprising administering to a subject, including a human subject, an antibody or antibody fragment that binds LPA.03-17-2011
20110135652Novel Use of Idbf - There are provided Idbf (inhibitor of Dvl and Bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/β-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/β-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/β-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/β-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/β-catenin signaling pathway.06-09-2011
20110086039Methods of Treating Liver Fibrosis and Pre-Cirrhosis with Epidermal Growth Factor Receptor Inhibitors - This invention relates generally to a therapeutic use of epidermal growth factor receptor inhibitors to reduce fibrosis, e.g., liver fibrosis, or pre-cirrhosis in a subject.04-14-2011
20100136021TGF-BETA BINDING ANTIBODIES - The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for mating cell proliferative disorders in a mammal.06-03-2010
20110081353ANTIBODY AGAINST THE CSF-1 R - The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.04-07-2011
20110256146NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.10-20-2011
20100260768ANTI MIF ANTIBODIES - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.10-14-2010
20090324605INTERFERON ALPHA ANTIBODIES AND THEIR USES - The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.12-31-2009
20110150895ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2 AND USE THEREOF - An antibody specifically binding to angiopoietin-2, and antigen-binding fragments thereof, and a use thereof are disclosed.06-23-2011
20090324604M-csf specific monoclonal antibody and uses thereof - M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.12-31-2009
20090028871NOVEL USE OF LIGANDS SPECIFIC TO FEX-2 POLYPEPTIDE - The present invention relates to novel use of a ligand specific to a FEX-2 polypeptide. More specifically, the present invention relates to methods for modulating the secretion of an inflammation-associated cytokine and for treating or preventing an inflammatory disease using the FEX-2-specific ligand. The ligand specific to the FEX-2 polypeptide can bind to FEX-2 expressed on the surface of phagocytes so that it can stimulate the secretion of anti-inflammatory cytokine and inhibit the secretion of inflammatory cytokine, so as to treat or prevent inflammatory diseases.01-29-2009
20110165167NOVAL MADCAM ANTIBODIES - The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease.07-07-2011
20100285021LIGANDS FOR USE IN THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HEMOSTASIS DISORDERS - The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.11-11-2010
20090136514Tetracyclines for Treating Ocular Diseases and Disorders - Methods and compositions are disclosed for treating a patient suffering from a condition associated with a retinal and/or choroidal disease or disorder of the eye involving endothelial cell dysfunction, especially vascular endothelial cells of the eye, and especially before or in the absence of neovascularization. The therapeutic method involves administering a tetracycline, an analog of tetracycline, or a chemically modified tetracycline (CMT) to a patient suffering from such conditions. Also provided are compositions and methods for reducing breakdown of tight junctions in vascular endothelial cells; reducing IL-1 α concentrations; and inhibiting IL-1 α-mediated matrix metalloproteinase activity in endothelial cells of the eye and surrounding tissues.05-28-2009
20100330096METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES - The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.12-30-2010
20110135651METHOD AND COMPOSITION FOR ENHANCING HEMATOPOIETIC STEM CELL MOBILIZATION - A therapeutic combination for improved mobilization of the hematopoietic stem and progenitor cells, and methods of use thereof are described. The therapeutic combination comprises G-CSF and an inhibitor of the EGFR signaling pathway. The role of EGFR is established by several lines of evidence, including use of quantitative trait locus analysis to map the chromosomal location of the non-G-CSF enhancement of hematopoietic stem and progenitor cells mobilization. Further, several different modes of inhibiting EGFR signaling all provide for an enhanced G-CSF induced mobilization of hematopoietic stem cells.06-09-2011
20110135650MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS - The present invention provides a compound of Formula (I)06-09-2011
20110262449METHOD FOR THE TREATMENT OF GOUT OR PSEUDOGOUT - The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.10-27-2011
20110052594AGENTS THAT DISSOLVE ARTERIAL THROMBI - Agents that induce platelet fragmentation include an IgG antibody that reacts with platelet epitope GPIIIA49-66 on platelet membrane, recombinant AMANTS-18, phorbol 12-myristate 13-acetate (PMA) and A23817.03-03-2011
20110052596ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof.03-03-2011
20110052595MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.03-03-2011
20110177089APOPTOSIS INDUCER - Provided is an agent which is useful for diagnosis, prevention, and treatment of various diseases induced by an oxidative stress. Disclosed are secreted eIF5A protein and a pharmaceutical containing the same.07-21-2011
20100166764ANTI-MYOSTATIN ANTIBODIES - Monoclonal anti-myostatin antibodies that preferentially bind myostatin over GDF-11, have strong binding affinity to myostatin and are resistant to chemical degradation. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment or prevention of various disorders in mammalian and avian species.07-01-2010
20100158922Anti-Interferon Gamma Antibodies and Methods of Use Thereof - The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and/or modulating the biological activities of IFNγ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.06-24-2010
20100196389METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE USE OF THE TREATMENT OF CANCER - Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).08-05-2010
20090175881ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof.07-09-2009
20110189190ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF - Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.08-04-2011
20080274120Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent - The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.11-06-2008
20100316649SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) - This disclosure concerns compounds which are useful as inhibitors of spleen tyrosine kinase (Syk) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of Syk. This disclosure also relates to pharmaceutical compositions containing these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.12-16-2010
20110117103ANTI-SWEAT ANTIGEN MONOCLONAL ANTIBODY - [Object of the Invention] To provide an antibody that inhibits histamine releasing activity induced by an antigenic substance contained in sweat.05-19-2011
20090291088THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS - The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies.11-26-2009
20090035315Method of Improving Treatments in Rheumatic and Arthritic Diseases - Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above.02-05-2009
20090285827ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8 ASSOCIATED DISORDERS - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.11-19-2009
20100111963METHOD FOR TREATING AGE-RELATED MACULAR DEGENERATION - A method is provided for administering to a mammal suffering from, or at risk for, age-related macular degeneration.05-06-2010
20100150933CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - A method of treating a nerve disorder mediated by nucleus pulposus in a mammal in need thereof, comprising: administering to said mammal a TNF-α inhibitor that is a monoclonal antibody which blocks TNF-α activity, thereby inhibiting TNF-α and treating said disorder.06-17-2010
20110027289METHOD FOR TREATING SYNOVIAL SARCOMA - Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.02-03-2011
20110171228Methods and Compositions Relating to the Regulation of Apoptosis by MUC1 and BH3-Containing Proapoptotic Proteins - This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or immune cell growth. The invention provides methods of inhibiting interactions between MUC1 and BH3-containing proapoptotic proteins, methods of inhibiting MUC1 expression, and methods of promoting apoptosis. Also provided are screening methods for compounds that inhibit interactions between MUC1 and BH3-containing proapoptotic proteins and pharmaceutical compositions of the same.07-14-2011
20120045444Treatment for Neoplastic Diseases - Administration of a mAb that specifically binds IL-1α is useful for treating tumor-associated diseases in human subjects.02-23-2012
20120045445METHOD OF TREATING VIRAL DISEASES - A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance with homeopathic technology. In order to obtain antibodies, human or heterologous interferon alpha, beta, or gamma, including recombinant interferon, is used; a mixture of various, mostly centimal, homeopathic dilutions being employed. A method of treating a pathologic syndrome, whose formation is affected by interferon, consists in the use of activated forms of antibodies to interferon alpha, beta, or gamma in low or ultra-low doses obtained by multiple consecutive dilutions and exposure to external factors.02-23-2012
20100047251ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USE THEREOF - The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.02-25-2010
20080206256Treatments for cancer - The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF), and methods for identifying such agents.08-28-2008
20120177654Method of treatment and agents useful for same - The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte/macrophage-type cells and/or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte/macrophage-type cells and/or reducing the production of inflammatory and pro-inflammatory mediators of these cells.07-12-2012
20120164152ANTI-IL-17F ANTIBODIES AND METHODS OF USE THEREOF - This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.06-28-2012
20120164151Methods for Treatment of Muscular Dystrophy - The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.06-28-2012
20120164150Monoclonal Antibodies Against Activated Protein C - The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies.06-28-2012
20100247545ANTIBODIES TO M-CSF - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.09-30-2010
20110182905MONOCLONAL ANTIBODIES THAT BIND TO HGM-CSF AND MEDICAL COMPOSITIONS COMPRISING SAME - Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.07-28-2011
20110182906FULLY HUMAN ANTIBODY TO HUMAN TNF-ALPHA, MOLECULAR EVOLUTION AND USE THEREOF - The present invention relates to the discovery and improvement of proteins that can specifically bind with human TNFa (Tumor Necrosis Factor alpha), the proteins are full human anti human TNFa monoclonal antibodies derived from human B cells. This invention disclosed the anti human TNFa monoclonal antibodies, their amino acid sequence of light chain comprising SEQ ID NO:8, and that of heavy chain comprising SEQ ID NO:16 or SEQ ID NO:18. This invention disclosed the coding genes of these antibodies, their Fab molecules, and their potential application to treat clinically the diseases related to TNFa, such as inflammation diseases.07-28-2011
20110182904ANTIBODIES TO BONE MORPHOGENIC PROTEINS AND RECEPTORS THEREFOR AND METHODS FOR THEIR USE - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Also provided are immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention and, optionally, one or more additional therapeutic. The invention also provides methods for treating diseases associated with abnormal bone formation and ossification mediated by BMP2, BMP4, BMPR1A, BMPR1B, ACTR15 and/or BMPR2.07-28-2011
20120219556Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases - The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.08-30-2012
20120251549COMPLEMENT INHIBITORS AND USES THEREOF - The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)10-04-2012
20120251548Treatment of Dermatological Pathologies - Skin inflammation in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.10-04-2012
20120171217Monoclonal Antibodies Against ANGPTL4 - Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.07-05-2012
20120076793AGENT FOR PROMOTING HEPATIC CELL REPLICATION AND AGENT FOR IMPROVING INSULIN RESISTANCE - The present invention aims at providing a medicament and a method for promoting replication of hepatocytes and a medicament and a method for ameliorating insulin resistance.03-29-2012
20100015161Composition Comprising In Vitro Expanded T-Lymphocytes and Vessel Formation Inhibitors Suitable in the Treatment of Cancer - Improved cancer therapy using a combination treatment with tumour-reactive T-lymphocytes obtained by an in vitro method for expansion and activation of tumour-reactive lymphocytes, in particular CD4+ helper and/or CD8+ T-lymphocytes and inhibitors of vessel formation inhibitors, notably inhibitors of VEGF.01-21-2010
20100008930METHOD FOR THE DIAGNOSIS OF LEUKEMIA - The present invention relates to a method for the diagnosis of the involvement of the central nervous system in a subject afflicted with leukemia. In particular, the present invention relates to the determination of the relative level or absolute amount of interleukin-15 (IL-15) and/or interleukin-15 receptor alpha chain (IL-15R alpha) in a sample from a subject afflicted with leukemia and comparing said level and/or amount with the level and/or amount of IL-15 and/or IL-15R alpha in a control sample. An elevated relative level and/or absolute amount of IL-15 and/or IL-15R alpha in the sample from a subject afflicted with leukemia relative to the control is indicative of the involvement of the central nervous system in leukemia and increased risk of relapse of leukemia and increased risk of relapse of leukemia.01-14-2010
20090060920DESACYL GHRELIN ANTIBODIES AND THERAPEUTIC USES THEREOF - A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment or prevention of obesity and related disorders including, for example, Type II non-insulin dependent diabetes mellitus (NIDDM), Prader-Willi syndrome, eating disorders, hyperphagia, and impaired satiety. Additionally, such antibodies can be useful for the treatment or prevention of other disorders, including anxiety, gastric motility disorders (including e.g., irritable bowel syndrome and functional dyspepsia), insulin resistance syndrome, metabolic syndrome, dyslipidemia, atherosclerosis, hypertension, hyperandrogenism, polycystic ovarian syndrome, cancer, and cardiovascular disorders by administering a therapeutically effective amount of an anti-desacyl ghrelin monoclonal antibody of the invention.03-05-2009
20120315279COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION - A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.12-13-2012
20120258114HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K10-11-2012
20110123542CCL20-SPECIFIC ANTIBODIES FOR CANCER THERAPY - The invention is directed to the field of cancer therapy, specifically to the use of anti-CCL20 antibodies for the treatment of neoplastic disorders. The invention provides compositions and methods useful for the treatment of CCR6 and CX-CR4 expressing tumors.05-26-2011
20120231011ANTI-VEGF MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY - The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.09-13-2012
20080299129ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 AND METHODS OF USE - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.12-04-2008
20100233180ANTIBODIES THAT BIND TO AN EPITOPE ON THE HUNTINGTON'S DISEASE PROTEIN - The present invention relates generally to the generation and characterization of anti-huntingtin antibodies binding an epitope on the Huntington's disease protein. The invention further relates to the use of such anti-huntingtin antibodies in the diagnosis and treatment of Huntington's disease.09-16-2010
20100233179BAFF, inhibitors thereof and their use in the modulation of B-cell response - The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.09-16-2010
20110243951IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS AND IMMUNOTOXINS - It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other things, to treat disease caused by asthma and chronic inflammation such as for example inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.10-06-2011
20120282266ANTI-NEOPLASTIC USES OF ARTEMIN ANTAGONISTS - The invention relates to methods for the prophylaxis and treatment of breast cancer using one or more antagonists of artemin function, such as anti-artemin polynucleotides or anti-artemin antibodies and antibody fragments, and uses of these antagonists. In particular, the invention relates to the resensitisation of therapy-resistance breast cancer cells to anti-cancer therapies by antagonism of artemin functionality.11-08-2012
20130022610METHODS OF DECREASING GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH DYSLIPIDEMIA - Methods for treating abnormal glycosylated hemoglobin (HbA1c) levels in a patient in need thereof, wherein the provided methods comprise administering to a patient in need a therapeutically effective amount of an Interleukin-1β modulator. Also, the invention provides compositions comprising at least one lipid modifying agent and an IL-1β modulator.01-24-2013
20080233127IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS - The present invention relates to Imidazolopyrimidine Analogs, methods of making Imidazolopyrimidine Analogs, compositions comprising an Imidazolopyrimidine Analog, and methods for treating or preventing a PI3K-related disorder comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog. The invention also relates to methods for treating or preventing mTOR-related disorders comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog.09-25-2008
20130142809METHODS OF TREATMENT USING AN IFN gamma INHIBITOR - The invention encompasses methods of treatment of interferon gamma (IFN-γ)-mediated diseases using IFN-γ inhibitors, such as anti-huIFN-γ antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-γ inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-γ antibody.06-06-2013
20130171161METHOD AND COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY OR ASSOCIATED WITH HIV - The invention provides a combination pharmaceutical composition comprising a) at least one activated-potentiated form of an antibody to at least one cytokine or at least an activated-potentiated form of an antibody to at least one receptor; and b) an effective amount of a nucleoside reverse transcriptase inhibitor, wherein said at least one cytokine or at least one receptor is participating in the regulation of immune process. Various embodiments and variants are contemplated.07-04-2013
20130171162COMPOSITIONS AND METHODS FOR THE PREVENTION OF OXIDATIVE DEGRADATION OF PROTEINS - The invention relates to pharmaceutical formulations comprising a protein and free methionine in combination with one or more compounds capable of preventing the oxidation of aromatic amino acid residues within a protein. More specifically, the invention relates to stabilized, pharmaceutically effective preparations of oxidation-sensitive therapeutic agents. The invention further relates to a method of inhibiting the oxidation of such therapeutic agents.07-04-2013
20130136750ANTIBODIES WHICH BIND FACTOR VIII - The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.05-30-2013
20130115220METHOD FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME - The present invention aims to provide a method for the prophylaxis or treatment of metabolic syndrome, which can discontinue the domino effect-like chain of diseases in metabolic syndrome in the upstream by suppressing infiltration of macrophage into the adipose tissues. The present invention provides a method for the prophylaxis or treatment of a metabolic syndrome, including a step of administering an AIM inhibitor to a subject.05-09-2013
20130101598ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.04-25-2013
20130142808ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION - The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.06-06-2013
20100316650SOLUBLE MIC POLYPEPTIDES AS MARKERS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR CONDITIONS - The present invention provides prognostic and diagnostic methods for cancer, as well as methods for monitoring or staging cancer. Methods involve assaying for tumor-derived soluble MIC polypeptide—either MICA or MICB or both—in a sample from a subject. Assays can be implemented with a MIC polypeptide binding agent such as a MIC polypeptide antibody or recombinantNKG2D. An ELISA sandwich assay is employed in some embodiments of the invention to identify a soluble MIC polypeptide. In additional embodiments, a sample is assayed for tumor cell-surface bound MIC in addition to assaying for soluble MIC. The invention also provides methods of cancer therapy involving detecting cancer in the subject by assaying for soluble MIC polypeptide and then administering a cancer therapy.12-16-2010
20110274698Immunomodulation Of Inflammatory Conditions Utilizing Follistatin-Like Protein-1 And Agents That Bind Thereto - Follistatin-like protein (FSTL-1) is a secreted glycoprotein of unknown function, first isolated from mouse osteoblastic cells as a transforming growth factor-β1-inducible gene. The inventors have discovered that FSTL-1 is a proinflammatory mediator. As such, the invention provides for composition and methods of using agents that bind to FSTL-1 to modulate various types of inflammation (e.g., autoimmune diseases). Inhibitors and antagonists of FSTL-1, particularly antibodies or antibody fragments, may be used to treat conditions related to inflammation, such as arthritis. In addition, the inventors have discovered that FSTL-1 has a role in the Th17 pathway. Accordingly, the invention provides for compositions and methods of using agents which bind to FSTL-1 to modulate the generation of Th17 cells. Such agents are useful for delaying development of and treating diseases associated with undesired production of Th17 cells, such as autoimmune diseases. Furthermore, since FSTL-1 is a proinflammatory mediator with a role in cancer, the invention provides for compositions and methods of using a pharmaceutical composition of FSTL-1 to delay development of or treat cancer.11-10-2011
20110311548USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO TREAT ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM - The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists. The invention further provides a method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist.12-22-2011
20110311547Arthritis Treatment - Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis.12-22-2011
20130189273EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE - The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.07-25-2013
20130189274PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS - Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.07-25-2013
20120093827TREATMENT OF AUTOIMMUNE DISORDERS WITH A NEUROTOXIN - Methods of treating one or more autoimmune disorders include a step of administering a Clostridial neurotoxin, such as a 04-19-2012
20130209482MONOCLONAL ANTIBODIES TO BASIC FIBROBLAST GROWTH FACTOR - The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.08-15-2013

Patent applications in class Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, etc.); or binds serum protein, plasma protein (e.g., tPA, etc.), or fibrin